Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.95
-0.1000-1.24%
Post-market: 7.950.00000.00%16:27 EDT
Volume:6.83M
Turnover:54.14M
Market Cap:8.43B
PE:-8.04
High:8.02
Open:7.88
Low:7.84
Close:8.05
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.73
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-8.05
PE(LYR):-20.81

Loading ...

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 06

ImmunityBio presents new ANKTIVA+BCG comparative data in NMIBC CIS at AUA 2026

Reuters
·
May 05

A Look At ImmunityBio (IBRX) Valuation As ANKTIVA Rollout Drives Rapid Product Revenue Growth

Simply Wall St.
·
May 03

ImmunityBio faces shareholder class action over alleged ANKTIVA promotion misstatements

Reuters
·
Apr 30

ImmunityBio announces annual shareholder meeting

Reuters
·
Apr 30

H.C. Wainwright Sticks to Its Buy Rating for ImmunityBio (IBRX)

TIPRANKS
·
Apr 30

Does ImmunityBio (IBRX) Expanding ANKTIVA to Saudi Arabia Redefine Its Global Oncology Strategy?

Simply Wall St.
·
Apr 28

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 21

ImmunityBio announces availability of ANKTIVA in Saudi Arabia

TIPRANKS
·
Apr 21

ImmunityBio launches ANKTIVA in Saudi Arabia, expanding Middle East presence

Reuters
·
Apr 21

Immunitybio Announces Anktiva® Is NOW Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of Mena Partnership

THOMSON REUTERS
·
Apr 21

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Apr 21

ImmunityBio hit with securities class action over ANKTIVA promotion claims

Reuters
·
Apr 16

Why Is ImmunityBio Stock Rallying Thursday?

Benzinga Earnings
·
Apr 10

Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD) and ImmunityBio (IBRX)

TIPRANKS
·
Apr 10

ImmunityBio Reports Preliminary Q1 Net Product Revenue

MT Newswires Live
·
Apr 09

Immunitybio Inc - Preliminary Q1 2026 Net Product Revenue $44.2 Mln, up 168% Year-Over-Year

THOMSON REUTERS
·
Apr 09

Press Release: ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

Dow Jones
·
Apr 09

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 08

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali

Reuters
·
Apr 07